Immunotherapy with CAR-T cells targeting CD19 has demonstrated great clinical success in hematologic malignancies.[5,6] Common toxic effects associated with CAR-T cell therapy include CRS and ICANS. This evidence concerns the gene CD19 and hematologic disorder.